| World-Acclaimed Leader in Field of
Hematopoietic and Mesenchymal Cell Therapies to Help Bring New Therapies
to Clinical Trials
HAIFA, Israel--(BUSINESS WIRE)--May 22, 2006--Pluristem Life Systems,
Inc. (OTC BB:PLRS
- News), a cell
therapy company dedicated to the commercialization of stem cell
products, today announced that Edwin M Horwitz, M.D., PhD. has joined
the Company's Scientific Advisory Board.
Professor Horwitz is a pioneer and world-renowned leader in the
clinical use of stem cells. He is recognized for his work on the
transplantation of pre-selected hematopoietic stem cells and for his
contribution to the field of mesenchymal cell therapy. Professor Horwitz
is the recipient and principal investigator of multiple NIH and other
grants in the field of mesenchymal cell therapy. Nature Medicine
published his first work, addressing use of bone marrow-derived
mesenchymal cells in children with osteogenesis imperfecta, in 1999.
Professor Horwitz is the chairman of the Mesenchymal Stem Cell
scientific committee of the International Society of Cellular Therapy (ISCT)
and co-chair of the committee on gene marking of the Center for
International Blood and Marrow Transplant Research. He is also an
editorial board member of several important international journals
including Biology of Blood and Marrow Transplantation, Stem Cells, Bone
Marrow Transplantation and Cytotherapy.
"We are honored by Prof. Horwitz's decision to join our company and to
help us in the development of Pluristem as a market leader in cell
therapy products. I'm sure that his expertise and experience will
contribute enormously to our product development and clinical programs,"
said Zami Aberman, CEO of Pluristem.
Prof Horwitz stated: "Pluristem is working hard on developing
technologies that aims to solve the global shortfall in matched tissue
for transplantation. This is a major unmet medical need and I look
forward to being able to contribute to Pluristem's exciting R&D
program."
Safe Harbor Statement
This press release contains statements, which may constitute
"forward-looking statements". Those statements include statements
regarding the intent, belief or current expectations of Pluristem Life
Systems, Inc., and members of our management as well as the assumptions
on which such statements are based. Forward-looking statements in this
release include that Dr. Horowitz will help us bring new therapies to
clinical trials; that he will help in the development of Pluristem as a
market leader in cell therapy products; that his expertise and
experience will contribute enormously to our product development and
clinical programs; that we are developing technologies to solve the
global shortfall in matched tissue for transplantation; that Dr.
Horowitz contribute to Pluristem's exciting R&D program. Actual outcomes
and our actual results could differ materially from those in such
forward-looking statements, as we may find that Dr. Horowitz is unable
or unwilling to commit the time necessary to make a serious contribution
to our research and development; that we are unable to retain Dr.
Horowitz's services; that our processes do not work as well in practice
as in theory; we may encounter side effects or other adverse
consequences of using our technology; our current patents may be
attacked and defeated in patent proceedings; our patent filings may be
rejected by the patent offices; other companies may discover and develop
better or cheaper technologies that would render our processes obsolete;
and we may not have sufficient funding to develop our technology. As
well, our products may never develop into useful products and even if
they do, they may not be approved for sale to the public. For further
risk factors see the Company's latest 10-KSB filed with the SEC.
For more information visit our website at
www.pluristem.com
|
